Survival curves based on CD38 expression, β₂-microglobulin, soluble CD23 (sCD23), soluble Bcl-2 (sBcl-2), and soluble APO1/Fas (sAPO1/Fas) levels.

(A) Kaplan-Meier plot comparing survival based on the detection of more than 30% (CD38⁺) or less than 30% CD38⁺(CD38⁻) B-CLL cells (> 30%, 50 cases; < 30%, 118 cases). Less than 30% CD38⁺ patients experienced a significantly longer survival (P < .00001). (B) B-CLL patients with β₂-microglobulin less than 2200 μg/mL (71 cases) showed a significant longer survival as compared with patients with β₂-microglobulin more than 2200 μg/mL (94 cases;P = .00041). None of the patients in the group with β₂-microglobulin less than 2200 μg/mL died during the follow-up period. (C) A very significant longer survival (P = .00001) was found in 83 patients with less than 60 sCD23 U/mL as compared with 84 cases with more than 60 U/mL. (D) Seventy-nine patients with more than 240 U/mL sBcl-2 showed a worse outcome (P = .005) in comparison with 72 cases with less than 240 U/mL sBcl-2. (E) Lack of sAPO1/Fas expression identified 93 patients with a longer survival (P = .008) in comparison with 68 cases with sAPO1/Fas⁺ expression.